Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Feb 2, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Executive appointments to strengthen financial and legal leadership during the transformation of the company St. Gallen, Switzerland, 02 February 2022...
-
Jan 19, 2022
First orally administered therapy for the treatment of the two main types of ANCA-associated vasculitis approved in Europe First launches expected in H1 2022 St. Gallen, Switzerland, 19 January...
-
Jan 18, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia and St. Gallen, Switzerland, 18 January 2022 – CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global...
-
Dec 21, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Phase-IIIb trial demonstrates statistically significant outcome on the primary endpoint Largest study to date showing benefit of Veltassa® (patiromer)...
-
Dec 20, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Abbreviated New Drug Application (ANDA) disputes regarding Injectafer® (ferric carboxymaltose) have now been settled St. Gallen, Switzerland, and...
-
Dec 16, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Focus on expansion in nephrology, and to maximize opportunities on the iron portfolio Vifor Pharma to divest non-core assets on finished drug product...
-
Dec 14, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Agreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent...
-
Dec 13, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR St. Gallen, Switzerland, 13 December 2021 – Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is...
-
Dec 10, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR St. Gallen, Switzerland, and Uniondale, NY,– 10 December 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced results from...
-
Dec 10, 2021
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Hervé Gisserot will join Vifor Pharma as Chief Commercial Officer on 17 January 2022 Responsibilities of Sales, Marketing and Market Access to be...